1: Giving docetaxel at the same time as ADT to men with metastatic prostate cancer extends overall survival by an average of 15 months – results from STAMPEDE
The much anticipated official results of the docetaxel arm of the STAMPEDE trial have been published in the Lancet. The trial reported an almost unprecedented survival benefit for men newly diagnosed with metastatic prostate cancer, when they were given docetaxel chemotherapy as a first line treatment alongside ADT. On average, men receiving ADT + docetaxel lived 15 months longer than those receiving ADT alone, the current standard of care.
Find out more about how we’ve been working with NHS England to ensure this research leads to a change in clinical practice here.